Important Information
If you are interested in applying for this study, please:
- read the study description.
- review the Visit Planner dates in your location and confirm that you are available for the stated dates.
- If you have not yet registered with us, click on the ‘Register’ button at the top of this page and answer the questions.
- If you have already registered with us, answer the pre-screening questions listed below and submit your interest.
We will then contact you to check your suitability and share the Participant Informed Consent Form for you to read.
Study Information
New Zealand Clinical Research is trialling an investigational medicine that could help people with inflammatory bowel disease (IBD). IBD describes a group of disorders involving the inflammation of the digestive tract, including Crohn’s disease and ulcerative colitis. This can cause symptoms such as diarrhoea, rectal bleeding, abdominal pain, fatigue, and weight loss. It is estimated that at least 20,000 New Zealanders live with IBD.
The study medication, RO7806881, is a bispecific antibody that is designed to target 2 pathways that are linked to IBD. By targeting these 2 pathways, RO7806881 may be an effective treatment in reducing the inflammation seen in IBD patients.
This is an investigational medication because it has not been approved by MedSafe or other drug regulatory authorities. Clinical trials involve an investigational drug and some study assessments.
This study 2025 FULL 23850 is being funded by F. Hoffmann-La Roche Ltd and has been approved by the Health and Disability Ethics Committee.
Requirements
Healthy Males and Females
- Aged between 18 – 50 years
- Weigh at least 40kg
- BMI (Body Mass Index) between 18 – 32 kg/m2
- Smokers/Vapers (less than 10 per day) allowed
- Not currently taking any regular prescription medications (e.g., anti-depressants)
What is Involved?
Study Visits: 3-night stay + 11 clinic visits
Payment: $5,700 before tax